Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells

详细信息    查看全文

• 作者：Zhezhu Han ; Seungha Lee ; Suyeon Je ; Chi-Yong Eom ; Hye Jin Choi ; Jae J. Song…
• 关键词：Survivin ; TRAIL ; Gemcitabine ; Pancreatic cancer ; shRNA ; Oncolytic adenovirus
• 刊名：Apoptosis
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：21
• 期：3
• 页码：351-364
• 全文大小：6,938 KB
• 参考文献：1.Kim MP, Gallick GE (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res: Off J Am Assoc Cancer Res 14:1284–1285CrossRef
  2.Hilbig A, Oettle H (2008) Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther 8:511–523CrossRef PubMed
  3.Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617CrossRef PubMed
  4.Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C et al (2011) Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15:817–828PubMedCentral CrossRef PubMed
  5.Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J et al (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Nat Cancer Inst 107:dju413
  6.Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F (2015) Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 6:8255–8260PubMedCentral CrossRef PubMed
  7.Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921CrossRef PubMed
  8.Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y et al (2004) Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther: J Am Soc Gene Ther 10:162–171CrossRef
  9.Altieri DC (2008) New wirings in the survivin networks. Oncogene 27:6276–6284PubMedCentral CrossRef PubMed
  10.Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006) Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 41:1431–1440CrossRef PubMed
  11.Kanwar JR, Kamalapuram SK, Kanwar RK (2013) Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev 33:765–789CrossRef PubMed
  12.Liu WS, Yan HJ, Qin RY, Tian R, Wang M, Jiang JX et al (2009) siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 54:89–96CrossRef PubMed
  13.Yoon DH, Shin JS, Jin DH, Hong SW, Jung KA, Kim SM et al (2012) The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res 32:1681–1688PubMed
  14.Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61–70CrossRef PubMed
  15.Zhang R, Ma L, Zheng M, Ren J, Wang T, Meng Y et al (2010) Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther 17:275–288CrossRef PubMed
  16.Li QX, Zhao J, Liu JY, Jia LT, Huang HY, Xu YM et al (2006) Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 5:860–866CrossRef PubMed
  17.Ambrosini G, Adida C, Sirugo G, Altieri DC (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273:11177–11182CrossRef PubMed
  18.Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805–2809PubMed
  19.Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N (2002) Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Investig 109:285–286PubMedCentral CrossRef PubMed
  20.Shen W, Wang CY, Wang XH, Fu ZX (2009) Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 28:81PubMedCentral CrossRef PubMed
  21.Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853–3861CrossRef PubMed
  22.Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628–8633CrossRef PubMed
  23.Kauh J, Fan S, Xia M, Yue P, Yang L, Khuri FR et al (2010) c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS ONE 5:e10376PubMedCentral CrossRef PubMed
  24.Fulda S, Meyer E, Debatin KM (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21:2283–2294CrossRef PubMed
  25.Zhu H, Guo W, Zhang L, Davis JJ, Wu S, Teraishi F et al (2005) Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther 4:393–397PubMed
  26.Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228–237CrossRef PubMed
  27.Premkumar DR, Jane EP, Foster KA, Pollack IF (2013) Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther 346:201–210PubMedCentral CrossRef PubMed
  28.He SQ, Rehman H, Gong MG, Zhao YZ, Huang ZY, Li CH et al (2007) Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. Cancer Biol Ther 6:1247–1257PubMed
  29.Xu ZW, Kleeff J, Friess H, Buchler MW, Solioz M (2003) Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 23:251–258PubMed
  30.Mao L, Yang C, Li L, Nai L, Fan L, Wang J et al (2014) Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells. Tumour Biol: J Int Soc Oncodev Biol Med 35:5937–5944CrossRef
  31.Yang J, Ouyang J, Ouyang L, Ouyang L, Chen Y (2013) Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells. Oncol Res 21:43–50CrossRef PubMed
  32.Retzer-Lidl M, Schmid RM, Schneider G (2007) Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer 121:66–75CrossRef PubMed
  33.Kim SY, Kang S, Song JJ, Kim JH (2013) The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy. Int J Oncol 42:1337–1348PubMed
  34.Seol DW, Billiar TR (1999) A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem 274:2072–2076CrossRef PubMed
  35.Seol JW, Chaudhari AA, Lee YJ, Kang HS, Kim IS, Kim NS et al (2007) Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep 18:523–529PubMed
  36.Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, Lopez-Rios F, Fujiwara K, Matsui WH et al (2010) A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 9:2582–2592PubMedCentral CrossRef PubMed
  37.Arlt A, Muerkoster SS, Schafer H (2013) Targeting apoptosis pathways in pancreatic cancer. Cancer Lett 332:346–358CrossRef PubMed
  38.Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, Koczan D et al (2001) Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23:72–79CrossRef PubMed
  39.Alemany R (2012) Chapter four-design of improved oncolytic adenoviruses. Adv Cancer Res 115:93–114CrossRef PubMed
  40.Alemany R (2013) Viruses in cancer treatment. Clin Trans Oncol: Offl Publ Fed Span Oncol Soc Nat Cancer Inst Mexico 15:182–188CrossRef
  41.Sharma A, Tandon M, Bangari DS, Mittal SK (2009) Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther 4:117–138PubMedCentral CrossRef PubMed
  42.Kang S, Kim JH, Kim SY, Kang D, Je S, Song JJ (2014) Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus. Biochem Biophys Res Commun 453:480–485CrossRef PubMed
  
• 作者单位：Zhezhu Han (1) (2) (5)
  Seungha Lee (1)
  Suyeon Je (1)
  Chi-Yong Eom (3)
  Hye Jin Choi (4)
  Jae J. Song (1) (5)
  Joo-Hang Kim (4)
  
  1. Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea
  2. Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, Jilin Province, People’s Republic of China
  5. Severance Biomedical Science Institute, Yonsei University, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea
  3. STEREO Imaging Group, Seoul Center, Korea Basic Science Institute, Seoul, Republic of Korea
  4. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  Cell Biology
  Biochemistry
  Virology
  
• 出版者：Springer Netherlands
• ISSN：1573-675X

文摘

In this study, we demonstrated that survivin downregulation with TRAIL expression greatly enhanced the cytotoxic death of pancreatic cancer cells after gemcitabine treatment. Using real-time RT-PCR, we analyzed five survivin shRNAs to identify the best target sequence for suppression of human survivin, with the goal of treating gemcitabine-resistant pancreatic cancer cells. Survivin shRNA 5, corresponding to target 5, showed the greatest reduction in survivin mRNA levels. Furthermore, combined treatment with survivin shRNA-expressing adenovirus with gemcitabine plus TRAIL decreased uncleaved PARP and increased consequent PARP cleavage, which was correlated with the greatest levels of survivin downregulation and cell death. These results indicate that survivin functions as a common mediator of gemcitabine- and TRAIL-induced cell death. Using a nude mouse model implanted with MiaPaCa-2 pancreatic cancer cells, we observed tumor regression induced by an oncolytic adenovirus expressing survivin shRNA and TRAIL plus gemcitabine. Together, our findings provide a strong rationale for treating pancreatic cancer patients with both gemcitabine and oncolytic adenovirus armed with survivin shRNA and TRAIL. Keywords Survivin TRAIL Gemcitabine Pancreatic cancer shRNA Oncolytic adenovirus